Metabolites derived from any human flavin-containing monooxygenase (FMO) subtype can now be produced as a service offering at Hypha. Recombinant enzymes of all five forms of human FMOs have been cloned into E.coli to provide a mechanism to access scalable quantities of FMO derived metabolites. FMO3, the most prominent form in human liver and associated with the bulk of hepatic FMO-mediated metabolism, is also available as part of Hypha’s PolyCYPs+ kit together with 18 PolyCYP isoforms and human AOX1 for accessing phase I oxidised metabolites.
Read more here.